Table 1.

Characteristics of the patients at the initial visit (N = 58).

Characteristic	Placebo (N = 27)	Pravastatin (N = 31)	P Value
Age (year)	15 ± 4	16 ± 3	0.82
% Female	59	55
Race
% White	93	100
% Black	7	0
% Other	0	0
Height (cm)	161 ± 15	167 ± 16	0.16
Weight (kg)	56 ± 20	67 ± 23	0.05
Urine microalbumin excretion (mcg/min)
Mean	42 ± 96	19 ± 23	0.25
Median	15 [7, 23]	10 [7, 19]
Left ventricular mass index (g/m2)	53 ± 11	55 ± 13	0.65
Total kidney volume (ml)
Mean	565 ± 375	545 ± 250	0.81
Median	489 [322, 663]	493 [324, 668]
Total kidney volume corrected for height (ml/m)
Mean	342 ± 213	321 ± 136	0.67
Median	278 [196, 386]	287 [200, 372]
Serum creatinine (mg/dl)
Mean	0.6 ± 0.2	0.7 ± 0.2	0.31
Median	0.6 [ 0.5, 0.7]	0.7 [0.6, 0.8]
24-h urine creatinine clearance (ml/min per 1.73 m2)	142 ± 34	140 ± 32	0.80
BP (mmHg)
Systolic	119 ± 11	122 ± 11	0.42
Diastolic	72 ± 7	72 ± 7	0.97
24-h urine protein (g/day)
Mean	0.16 ± 0.20	0.11 ± 0.05	0.25
Median	0.11 [ 0.09, 0.12]	0.10 [0.07, 0.14]
Hematocrit (%)	39 ± 3	41 ± 3	0.03
Cholesterol
HDL	49 ± 11	48 ± 13	0.78
LDL	94 ± 22	85 ± 23	0.14
Total	157 ± 26	145 ± 25	0.07

Samples from the same patients were available at the baseline and the 36-month time points (as reported in¹²). Values are the mean ± SD or median [25th percentile, 75th percentile]. P < 0.05 considered significant (bolded).